Insulin Lispro (U100)

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Type 2 DiabetesType 2 Diabetes Treated With Insulin

Phase 3

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

CompletedNCT04537923

Eli Lilly and CompanyType 2 Diabetes

Start: 2020-10-19End: 2022-11-01Updated: 2023-11-02

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

CompletedNCT05462756

Eli Lilly and CompanyType 2 Diabetes, Type 2 Diabetes Treated With Insulin

Start: 2022-08-11End: 2024-02-27Updated: 2025-04-27

Related Papers

Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program.

2026-01-27

Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.

2025-06-228 citations

Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).

2024-07-152 citations

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes

JAMA2023-10-03115 citations

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.

2022-06-1615 citations